Rituximab + Autologous dendritic cells + GM-CSF + Pembrolizumab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Follicular Lymphoma
Conditions
Follicular Lymphoma
Trial Timeline
Jan 1, 2016 → Feb 1, 2021
NCT ID
NCT02677155About Rituximab + Autologous dendritic cells + GM-CSF + Pembrolizumab
Rituximab + Autologous dendritic cells + GM-CSF + Pembrolizumab is a phase 2 stage product being developed by Merck for Follicular Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02677155. Target conditions include Follicular Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02677155 | Phase 2 | Completed |
Competing Products
20 competing products in Follicular Lymphoma